Bank of America spends $250 million a year on GLP-1 drugs for staff

Bank of America's CEO revealed the company spends $250 million a year on GLP-1 drugs such as Ozempic and Wegovy as part of its employee health coverage. Employers are grappling with soaring demand for the medications, which can cost thousands of dollars per patient annually. The figure highlights the growing financial burden large companies face due to rising uptake of obesity drugs.